Фармакоэпидемиология эпидемиологик методлардан фойдаланган ҳолда аҳоли ёки одамларнинг катта гуруҳлари даражасида реал шароитларда дори воситаларнинг самарадорлигини, хавфсизлигини ва улардан фойдаланишни ўрганадиган фан. Фармакоэпидемиологик тадқиқотлар натижалари энг самарали ва хавфсиз дори-дармонлардан оқилона ва арзон фойдаланишга ёрдам бериши керак. Тадқиқотда ташқи кўриниш тарихи ва фармакоэпидемиологик тадқиқотларнинг асосий усуллари тасвирланган.
Фармакоэпидемиология эпидемиологик методлардан фойдаланган ҳолда аҳоли ёки одамларнинг катта гуруҳлари даражасида реал шароитларда дори воситаларнинг самарадорлигини, хавфсизлигини ва улардан фойдаланишни ўрганадиган фан. Фармакоэпидемиологик тадқиқотлар натижалари энг самарали ва хавфсиз дори-дармонлардан оқилона ва арзон фойдаланишга ёрдам бериши керак. Тадқиқотда ташқи кўриниш тарихи ва фармакоэпидемиологик тадқиқотларнинг асосий усуллари тасвирланган.
Фармакоэпидемиология – это наука, изучающая с помощью эпидемиологических методов эффективность, безопасность и особенности использования лекарственных средств в реальных условиях на уровне популяции или больших групп людей. Результаты фармакоэпидемиологических исследований должны способствовать рациональному и приемлемому с точки зрения соотношения стоимость/эффективность применению наиболее эффективных и безопасных лекарственных средств. В обзоре описаны история появления и основные методы фармакоэпидемиологических исследований.
Pharmacoepidemiology is a science that studies the effectiveness, safety, and features of the medicines usage in real conditions at the level of a population or large groups of people using epidemiological methods. The results of pharmacoepidemiological studies should help to rational and acceptable usage of the most effective and safe drugs, in terms of cost/effectiveness ratio. This review presents the history of appearance and the main methods of pharmacoepidemiologic studies
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Mavlyanov I.R. | RSTIAM | |
| 2 | Yakubov A.K. | RSTIAM | |
| 3 | Qosimov A.S. | RSTIAM |
| № | Ҳавола номи |
|---|---|
| 1 | 1. Флетчер Р., Флетчер С., Вагнер Е. Клиническая эпидемиология. Основы доказательной медицины. – 3-е изд./ Пер. с англ.; Под ред. С.Е. Бащинского, С.Ю. Варшавского. – М.: Медиа Сфера, 1998. |
| 2 | 2. Anonymous (Boston Collaborative Drug Surveillance Program). Regular aspirin intake and acute myocardial infarction // Brit. Med. J. – 1974. – Vol. 1. – P. 440-443. |
| 3 | 3. Bombardier C. Research challenges; overview of epidemiological study design // J. Reumatol. – 1998. – Vol. 15 (Suppl 17). – P. 5-8. |
| 4 | 4. Brodie D.C. Drug utilization review: planning // Hospitals. – 1972. – Vol. 46. – P. F03-12. |
| 5 | 5. Einarson T.R., Bergman U., Wiholm B.-E. Principles and practice of pharmacoepidemiology // Speight T.M., Holford N.H.G.; editors. Avery’s Drug Treatment. – 4th ed. – New Zealand: Adis International Limited, 1997. – P. 371-392. |
| 6 | 6. Hartzema A.G. Pharmacoepidemiology - its relevance to clinical practice // J. Clin. Pharm. Ther. – 1992. – Vol. 17. – P. 73-74. |
| 7 | 7. Hartzema A.G., Porta M.S., Tilson H.H. Pharmacoepidemiology: an introduction. – 2nd ed. – Cincinnati: Harvey Whitney Books, 1991 |
| 8 | 8. Hartzema A.G., Tilson H.H., Chan K.A. The contribution of pharmacoepidemiology to the study of drug uses and effects, and risk management // Hartzema A.G., Tilson H.H., Chan K.A.; editors. Pharmacoepidemiology and therapeutic risk assessment. – Cincinnati: Harvey Whitney Books, 2008. – P. 1-38. |
| 9 | 9. Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women // New Engl. J. Med. – 1971. – Vol. 284. – P. 878-881 |
| 10 | 10. Jick H., Rodriguez L.A.G., Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects // Lancet. – 1998. – Vol. 352. – P. 1767-1770 |
| 11 | 11. Kennedy D. Assessing national drug utilization in the United States. WHO Drug Utilization Research Group Meeting. – Washington, 1983. |
| 12 | 12. Lee D., Bergman U. Studies of drug utilization. In: Strom B.L., editor. Pharmacoepidemiology. – 2nd ed. – N. York: John Wiley & Sons, Inc., 1994. – P. 379-395. |
| 13 | 13. Lee J.A.H., Draper P.A., Weatherall M. Prescribing in three English towns // Milbank Mem. Fund. Q. – 1965. – Vol. 43. – P. 285-290. |
| 14 | 14. McBride W.G. Thalidomide and congenital abnormalities // http://medsport.uz 35 Lancet. – 1961. – Vol. 2. – P. 1358. |
| 15 | 15. Meade T.W. Prescribing of chloramphenicol in general practice // Brit. Med. J. – 1967. – Vol. 1. – P. 671-674. |
| 16 | 16. Neutel C.I. The status of pharmacoepidemiology in a regulatory environment // Pharmacoepidemiol. Drug Saf. – 2000. – Vol. 9. – 65-70. |
| 17 | 17. Porta M.S., Hartzema A.G. The contribution of epidemiology to the study drugs // Drug Int. Clin. Pharm. – 1987. – Vol. 21. – P. 741-747. |
| 18 | 18. Ronning M. Setting-up the WHO ATC classification of drugs and the Defined Daily Dose – problems and potential for standardizing drug use research worldwide // McGavock H.; editor. Handbook of Drug Use Research Methodology. – 1st ed. – Newcastle: The United Kingdom Drug Utilization Research Group, 2000. – P. 1-9 |
| 19 | 19. Serradel J.S., Bjornson D.C., Hartzema A.G. Drug utilization study methodologies: national and international perspectives // Drug Int. Clin. Pharm. – 1987. – Vol. 21. – P. 994-1001. |
| 20 | 20. Spitzer W.O., Lewis M.A., Heinemann L.A.J. et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study // Brit. Med. J. – 1996. – Vol. 312. – P. 83-88. |
| 21 | 21. Strom B.L. Study designs available for pharmacoepidemiology studies // Strom B.L.; editor. Pharmacoepidemiology. – 3d ed. – N. Y.: John Wiley & Sons, Inc., 2000. – P. 17-30. |
| 22 | 22. Strom B.L. What is pharmacoepidemiology? // Strom B.L.; editor. Pharmacoepidemiology. – 3d ed. – N. Y.: John Wiley & Sons, Inc., 2000. – P. 3-16. |
| 23 | 23. Strom B.L. When should one perform pharmacoepidemiology studies? // Strom B.L.; editor. Pharmacoepidemiology. – 3nd ed. – N. Y.: John Wiley & Sons, Inc., 2000. – P. 63-72. |
| 24 | 24. Tilson H.H. Pharmacoepidemiology: the future // Drug Int. Clin. Pharm. – 1988. – Vol. 22. – P. 416-421. 32 |
| 25 | 25. Urquhart J. Role of pharmacoepidemiology in drug development // Int. J. Clin. Pharm., Ther. Toxicol. – 1992. – Vol. 30. – P. 456-458. |
| 26 | 26. Van Boxtel C.J. Wang G. Some observations on pharmacoepidemiology in Europe // Nethelands J. Med. – 1997. – Vol. 51. – P. 205-212. |
| 27 | 27. Verhamme K., Sturkenboom M. Study designs in paediatric pharmacoepidemiology // Europ. J. Clin. Pharmacol. – 2011. – Vol. 67. №1. – P. 67-74.28 |
| 28 | 28. Wettermark B. The intriguing future of pharmacoepidemiology // Europ. J. Clin. Pharmacol. – 2013. – Vol. 69, №1. – P. 43-51. |
| 29 | 29. WHO Drug Utilization Research Group (DURG). Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden // Europ. J. Clin. Pharmacol. – 1985. – Vol. 29. – P. 1-8. |
| 30 | 30. Wilson-Davis K. Study design and the use of statistics in drug use research // McGavock H.; editor. Handbook of Drug Use Research Methodology. – 1st ed. – Newcastle: The United Kingdom Drug Utilization Research Group, 2000. P. 36-55. |
| 31 | 31. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraception: results of international multicentre case-control study // Lancet. – 1995. – Vol. 346. – P. 1575-1582 |
| 32 | 32. World Health Organization Expert Committee. The selection of essential drugs. – Geneva: World Health Organization, 1977. |
| 33 | 33. Wright P. Untoward effects associated with practolol administration. Оculo-mucocutaneous syndrome // Brit. Med. J. – 1975. – Vol. 1. – P. 595-598 |